A Proof-of-Concept, Prospective, Open label, Randomized Controlled Clinical Study Evaluating RevitalVisionÂ® Therapy for Improving Uncorrected Visual Acuity (UCVA) and Contrast Sensitivity Function (CSF) in Cataract Patients Following Diffractive IOL Implantat.

one0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年3月6日

试验速览

暂无简介。

•1.Subject, man & woman 50 to 80 years old, post cataract surgery with Diffractive IOL implants 12 to 52 weeks following surgery.
•2.Subject with BCVA better than 6 of 9 at least in one eye.
•3.Subject with UCVA 6by6 â?? 6 of 15 at least in one eye.
•4.Subject with Contrast Sensitivity Function below-normal range, measured in FACT sine wave test chart during screening visit.
•5.Subject complaining on vision quality.
•6.Subject is able to sign on informed consent.
•7.Subject is willing and declare his/her motivation to practice 3 to 4 times per week x 30 minutes each training, for 8 consecutive weeks.
•8.Subject who is able to participate in complete ophthalmic and ocular evaluation based on the study PI decision.
•9.Subject has a Personal Computer with window OS or MAC IOs (Operating System) with screen size 15-26 inch at home and with internet connection.
•10.Subject pass successfully Computerized Evaluation 1 and 2 as defined by RV system.

•1.Subject who has unstable vision based on PI decision
•2.Subject with severe untreated attention disorder.
•3.Subject who suffer from chronic migraines based on subject self-reporting
•4.Subject who diagnosed with Epilepsy
•5.Subject who has any ocular disease beside cataract.
•6.Subject who has any behavioral or neurological disorders which may interfere with the study, based on PI discursion
•7.Subject who has any physical or mental impairment precluding study compliance, based on PI discursion
•8.Unstable health condition, which may prevent from completing the study and follow up visits. Based on PI decision.
•9.Treated with medication that may affect vision quality.

发起方